JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2022 Top Picks Conference January 25-27, 2022. As part of the virtual event, JTC partnered companies will provide a corporate presentation, followed by an interactive Q&A session.
All investors and interested parties will have the opportunity to submit questions live during the event. Additionally, interested participants may also pre-submit questions before the live event, which can be sent via the conference website at virtualinvestorco.com. Participating companies will answer as many questions as possible during the event.
The schedule for the event is as follows:
Tuesday, January 25, 2022
Wednesday, January 26, 2022
Thursday, January 27, 2022
About JTC Team
JTC is a fully integrated corporate communications firm that is dedicated to helping you tell your story to the right audiences in order to build awareness. JTC has developed a reputation of excellence for executing on robust communication strategies that deliver results. The Company partners with both public and private companies across the Life Sciences and Technology industries to help raise awareness and build stakeholder value. For more information, please visit www.jtcir.com or connect with the company on Twitter and LinkedIn.
Contact:
Jenene Thomas
JTC Team, LLC
T: +1 (833) 475-8247
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$8.21 |
Daily Change: | 0.67 8.89 |
Daily Volume: | 197,146 |
Market Cap: | US$100.490M |
June 25, 2025 May 08, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load